Related Experiment Video
Updated: Jul 25, 2026

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition
Published on: November 14, 2013
Melatonin Influences Bmi1+ Intestinal Stem Cell Fate Through Metabolic Regulation After Irradiation
Xudan Lei1,2, Zhenni Xu1,2, Xiangjun Liu1
1Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Provincial Engineering Research Center of Tumor Organoids and Clinical Transformation, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Abstract:
Radiation-induced intestinal injury involves catastrophic loss of intestinal stem cells (ISCs), but the mechanisms enabling their rescue remain elusive. Here, we demonstrated that melatonin, a potent mitigator of mitochondrial oxidative stress, robustly promoted the regeneration of intestinal crypts and organoids following irradiation. Using in vivo lineage tracing with Lgr5CreERT2;Rosa26-tdTomato, Mist1CreERT2;Rosa26-tdTomato, and Bmi1CreER;Rosa26-tdTomato models, we pinpointed Bmi1+ cells as the source of the melatonin-induced proliferating cells responsible for regeneration. Genetic ablation of Bmi1+ lineages abolished the regenerative benefits of melatonin. Mechanistically, melatonin was associated with a shift in mitochondrial metabolism in Bmi1+ ISCs, in part through the suppression of Ca2+/CaMKⅡ-driven phosphorylation of DRP1, which contributed to reduced reactive oxygen species (ROS) production. This attenuation of oxidative stress subsequently reduced DNA damage and cell cycle arrest, while enhancing mitochondrial oxidative phosphorylation. Crucially, pharmacological inhibition of p-DRP1 phenocopied the effects of melatonin, promoting Bmi1+ ISC-mediated regeneration. In conclusion, our work revealed that melatonin acts as a guardian of Bmi1+ ISCs and promotes regeneration by imposing a critical checkpoint on CaMKII/DRP1-dependent metabolic dysfunction. Targeting this pathway with melatonin or specific p-DRP1 inhibitors represents a novel and highly promising therapeutic strategy for radiation-induced intestinal injury.

